Crinetics Pharmaceuticals (CRNX) Investor Presentation - Slideshow

SAFE HARBOR STATEMENT CRINETICS PHARMACEUTICALS | 2 First Phase 3 readout expected in 2023 Clinical POC in highly prevalent indications Multiple programs in late clinical development De-risk and Accelerate Time to POC with Crinetics' Endocrine GPCR Discovery and Development Engine CRINETICS PHARMACEUTICALS | 4 • Understanding the biology and medicine is key • Every GPCR is different • Every assay cascade is different • No one technique will solve every challenge • No checklist can capture what makes a compo ...